Billiontoone, Inc. key statistics and ratios
In fiscal 2025, Billiontoone, Inc. had return on equity of 6.5%, an operating margin of 5.3%, debt equal to 11.9% of equity and a current ratio of 11.69. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|
| Gross margin | 24.1% | 53.0% | 68.3% | 71.3% |
| Operating margin | −96.9% | −30.9% | 5.3% | 10.9% |
| Net margin | −115.3% | −27.2% | 2.4% | 9.5% |
| Free-cash-flow margin | −83.4% | −30.7% | 5.2% | 8.3% |
| Return on equity | — | — | 6.5% | 7.4% |
| Return on assets | — | −13.8% | 1.6% | 5.5% |
| Asset turnover | — | 0.51 | 0.65 | 0.58 |
| Current ratio | — | 8.03 | 11.69 | 11.69 |
| Debt to equity | — | — | 11.9% | 17.0% |
| Interest cover (operating income ÷ interest) | n/m | n/m | 168.7x | — |
| Effective tax rate | — | — | 3.9% | 0.5% |
| R&D as % of revenue | 31.2% | 24.0% | 16.2% | 14.9% |
| SG&A as % of revenue | 89.8% | 59.9% | 46.9% | 45.5% |
| Capital spending as % of revenue | 8.6% | 3.5% | 2.9% | 3.1% |
| Free cash flow ÷ net income | — | — | 210.8% | 88.0% |
| Dividends and buybacks ÷ free cash flow | — | — | 0.0% | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 52.6% | 57.1% | 64.4% | 65.3% | 69.9% | 71.4% | 73.0% | 70.5% |
| Operating margin | −32.9% | −25.9% | −3.9% | −2.4% | 11.5% | 10.8% | 16.5% | 5.0% |
| Net margin | −38.8% | −25.5% | −6.8% | −0.4% | 6.8% | 6.2% | 16.6% | 7.4% |
| Free-cash-flow margin | — | −23.3% | 0.5% | −2.5% | 9.4% | 9.6% | 10.1% | 4.6% |
| Current ratio | — | 8.03 | — | — | 6.17 | 11.69 | 10.92 | 11.69 |
| Debt to equity | — | — | — | — | — | 11.9% | 17.8% | 17.0% |
| R&D as % of revenue | 24.9% | 24.4% | 17.7% | 17.7% | 15.5% | 14.8% | 13.6% | 15.8% |
| SG&A as % of revenue | 60.6% | 58.6% | 50.6% | 50.1% | 42.9% | 45.8% | 43.0% | 49.6% |
Financial health
- Short-term assets cover short-term liabilities $651m of assets due within a year against $56m of liabilities due within a year.
- Short-term assets cover long-term liabilities $651m short-term assets against $137m of longer-dated liabilities.
- More cash than debt $549m of cash against $91m of debt.
- Debt below 40% of shareholders' equity Debt is 17% of equity.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt $45m of operating cash flow against $91m of debt.
- Operating profit covers interest at least five times over Operating income of $43m against $41,000 of interest.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Compare with peers
- Twist Bioscience Corp statistics
- Castle Biosciences Inc statistics
- Fulgent Genetics, Inc. statistics
- Veracyte, Inc. statistics
- Schrodinger, Inc. statistics
Head to head: BLLN vs TWSTBLLN vs CSTLBLLN vs FLGT
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies